HRS4R
Vull donar
Firma
ARANTXA ERASO-URIÉN
Posició
Cap de Grup - R4
Caps de Grup - R4

Projectes

Codi oficial: Estudio PREV Data inici: 01/11/2021 Data fi: 31/12/2025 Investigador/a principal: ARANTXA ERASO URIÉN, SERGI MORAL TORRES Organisme finançador: FUNDACION MERCK SALUD
Codi oficial: ADARNAT I Data inici: 09/12/2022 Data fi: 09/12/2027 Investigador/a principal: LUIS MIGUEL ALONSO RUANO, ARANTXA ERASO URIÉN Organisme finançador: ASSOCIACIÓ ESPANYOLA CONTRA EL CÀNCER

Publicacions

Pla H, Fullana B, Esteve A, Fort-Culillas R, Ferrando-Díez A, Fernández-Ortega A, Pous A, Stradella A, Villanueva-Vázquez R, Cirauqui B, Falo C, Martínez-Pérez E, Molina G, Del Barco S, Eraso A, Margelí M, Viñas G, Gil-Gil M, Petriz L, Pernas S

Comprehensive Clinical Characterization and Long-Term Follow-Up of the Institut Català d'Oncologia Breast Cancer Observational Cohort Study.

Cancers, 2025, 17 dx.doi.org/10.3390/cancers17081366
Romera-Martínez I, Cancio IO, Buxó M, Martínez J, Fuentes-Raspall R, Urién AE, Vilanova JC

Heart substructure exposure during left breast cancer radiotherapy: a dosimetric comparison between hybrid VMAT and 3DCRT in free breathing and deep inspiration breath hold (DIBH).

Clinical & Translational Oncology, 2025, 27, 4177-4184 dx.doi.org/10.1007/s12094-025-03943-9
Lamy, J, Spoor, DS, Langendijk, JA, Vliegenthart, R, Eraso, A, Ventura, M, Santos, SCR, Fiúza, M, Kachenoura, N, Crijns, APG, Mousseaux, E

Cardiac MRI-based Subclinical Cardiac Dysfunction during 2 Years after Breast Cancer Irradiation: The MEDIRAD EARLY-HEART Study

Radiology-Cardiothoracic Imaging, 2025, 7 dx.doi.org/10.1148/ryct.240231
Marruecos Querol J, Jurado-Bruggeman D, Lopez-Vidal A, Mesía Nin R, Rubió-Casadevall J, Buxó M, Eraso Urien A

Contouring aid tools in radiotherapy. Smoothing: the false friend

Clinical & Translational Oncology, 2024, 26, 1956-1967 dx.doi.org/10.1007/s12094-024-03420-9
Corral J, Algara M, Muñoz-Montplet C, Eraso A, Giralt J, Defourny N, Lievens Y, Borras JM

Challenges in assessing national radiotherapy costs: application of the ESTRO-HERO model in Spain.

Frontiers in Public Health, 2024, 12, 1474376-1474376 dx.doi.org/10.3389/fpubh.2024.1474376
Romera-Mart nez, I, Oliveras, I, Bux , M, Mart nez, J, Raspall, RF, Urien, AE, Nadal, EP, Vilanova, JC

DOSIMETRIC COMPARISON OF HEART SUBSTRUCTURES FOR DIBH BETWEEN FREE BREATHING FOR BREAST CANCER

RADIOTHERAPY AND ONCOLOGY, 2024, 194, 640-641
Sanz, CA, Romera-Mart nez, I, Jurado-Bruggeman, D, Urien, AE, Raspall, RF

Radiotherapy for gastric lymphoma. A proposal for improving treatment delivery and reproducibility

RADIOTHERAPY AND ONCOLOGY, 2024, 194, 1168-1170
Mu oz-Montplet, C, Jurado-Bruggeman, D, Eraso, A, Fuentes-Raspall, R

The Impact of Advanced Algorithms on the Treatment of Meningiomas

RADIOTHERAPY AND ONCOLOGY, 2024, 194, 3452-3454
Bonet, M, Recalde, E, Soto, A, Martinez, A, Murcia, M, Mases, J, Fernandez, MN, Yufera, JC, Alvarez, A, Eraso, MA, Feltes, N, Hernandez, L, Bernard, P, Ramos, L, Garcia, V

Use of social media in radiation oncology: multicenter data from the GOCO Group

Reports of Practical Oncology and Radiotherapy, 2024, 29, 236-244 dx.doi.org/10.5603/rpor.100386
Sais, E, PLUJA, A., MONTAÑES, C., Bujons-Buscarons, E, PINEDA, F., Iguaran A, Roselló À, Hernández Martínez A, Teixidor-Vilà, E, ROMERA, A., Bosch-Barrera, J, ERASO, A., Oliva-Poch E

1062P Effect of the immunological circadian rhythm on the treatment of locally advanced non-small cell lung cancer treated with consolidation immunotherapy

ANNALS OF ONCOLOGY, 2024, 35, 1-1 dx.doi.org/10.1016/j.annonc.2024.08.1120

Formulari de contacte

Coneix l’IDIBGI!

menu